Penile squamous cell carcinoma · line 1 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | local_therapy |
| Linked regimen | None |
| ID | IND-PENILE-SCC-1L-ORGAN-SPARING |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-PENILE-SCC |
| Sources | SRC-EAU-PENILE-2024 |
Notes
STUB — Phase 1 (zero-content disease authoring pass). Transcribed from DIS-PENILE-SCC narrative (topical 5-FU/imiquimod for Tis; CO2-laser or wide local excision for T1a; glansectomy for selected T2) per EAU guidelines. No dedicated Surgery/Procedure entities authored for laser ablation / local excision / glansectomy (mirrors the no-regimen local_therapy pattern already used by IND-MF-EARLY-1L-SKIN-DIRECTED) — modality selection stays in prose pending a future Surgery-entity authoring pass. DRUG-IMIQUIMOD created as a new Drug stub (previously only mentioned in prose elsewhere in the KB). Requires urology / dermato-oncology co-lead signoff before clinical publication (CHARTER §6.1; dev-mode-exempted for draft merge).
Used By
Algorithms
ALGO-PENILE-SCC-1L- ALGO-PENILE-SCC-1L